UY30094A1 - Compuestos químicos - Google Patents
Compuestos químicosInfo
- Publication number
- UY30094A1 UY30094A1 UY30094A UY30094A UY30094A1 UY 30094 A1 UY30094 A1 UY 30094A1 UY 30094 A UY30094 A UY 30094A UY 30094 A UY30094 A UY 30094A UY 30094 A1 UY30094 A1 UY 30094A1
- Authority
- UY
- Uruguay
- Prior art keywords
- chemical compounds
- manufacture
- relates
- cancer
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000001093 anti-cancer Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 101000693265 Homo sapiens Sphingosine 1-phosphate receptor 1 Proteins 0.000 abstract 1
- 102100025750 Sphingosine 1-phosphate receptor 1 Human genes 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos químicos de fórmula (I) y (II): o sus sales farmac{ueitcamente aceptables, que presentan actividad antagonista de Edg-1 y son, por lo tanto, útiles por su actividad anti-cáncer y, de esta forma, en métodos de tratamiento del cuerpo humano o animal. La invención también se refiere a procesos para la fabricación de dichos compuestos químicos, a composiciones farmacéuticas que los contienen y a su uso en la fabricación de medicamentos para la producción de un efecto anti-cáncer en un animal de sangre caliente tal como el hombre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75943806P | 2006-01-17 | 2006-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY30094A1 true UY30094A1 (es) | 2007-08-31 |
Family
ID=38066557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY30094A UY30094A1 (es) | 2006-01-17 | 2007-01-15 | Compuestos químicos |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100197749A1 (es) |
| EP (1) | EP1979332A1 (es) |
| JP (1) | JP2009523774A (es) |
| KR (1) | KR20080094913A (es) |
| CN (1) | CN101370794A (es) |
| AR (1) | AR059138A1 (es) |
| AU (1) | AU2007206746A1 (es) |
| BR (1) | BRPI0706402A2 (es) |
| CA (1) | CA2636120A1 (es) |
| IL (1) | IL192591A0 (es) |
| TW (1) | TW200736234A (es) |
| UY (1) | UY30094A1 (es) |
| WO (1) | WO2007083089A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8022225B2 (en) | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| JP5035752B2 (ja) | 2006-02-03 | 2012-09-26 | 大正製薬株式会社 | トリアゾール誘導体 |
| JP5218737B2 (ja) | 2006-02-06 | 2013-06-26 | 大正製薬株式会社 | スフィンゴシン−１−リン酸結合阻害物質 |
| WO2008059238A1 (en) * | 2006-11-17 | 2008-05-22 | Astrazeneca Ab | Benzenesulfonamide compounds as edg-1 antagonists useful in the treatment of cancer |
| HRP20120363T1 (hr) * | 2007-08-01 | 2012-05-31 | Taisho Pharmaceutical Co. | Inhibitor vezivanja s1p1 |
| WO2009019506A1 (en) * | 2007-08-03 | 2009-02-12 | Astrazeneca Ab | Heterocyclyc sulfonamides having edg-1 antagonistic activity |
| KR20200117058A (ko) | 2008-07-23 | 2020-10-13 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체 |
| SI2342205T1 (sl) | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
| TW201117809A (en) * | 2009-09-25 | 2011-06-01 | Astellas Pharma Inc | Substituted amide compounds |
| JP5856980B2 (ja) | 2010-01-27 | 2016-02-10 | アリーナ ファーマシューティカルズ， インコーポレイテッド | （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス |
| SG183416A1 (en) | 2010-03-03 | 2012-09-27 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
| US9245267B2 (en) | 2010-03-03 | 2016-01-26 | Visa International Service Association | Portable account number for consumer payment account |
| PH12012500542A1 (en) * | 2010-09-24 | 2012-11-12 | Astellas Pharma Inc | Substituted amide compound |
| JP5776695B2 (ja) * | 2010-09-24 | 2015-09-09 | アステラス製薬株式会社 | 置換アミド化合物 |
| US20150368213A1 (en) * | 2014-06-20 | 2015-12-24 | The University of Montana, Missoula, MT | Novel Inhibitors of System Xc- |
| EP4445956A3 (en) | 2015-01-06 | 2024-12-04 | Arena Pharmaceuticals, Inc. | Compound for use in treating conditions related to the s1p1 receptor |
| PL3310760T3 (pl) | 2015-06-22 | 2023-03-06 | Arena Pharmaceuticals, Inc. | Krystaliczna sól L-argininy kwasu (R)-2-(7-(4-cyklopentylo-3-(trifluorometylo)benzyloksy)- 1,2,3,4-tetrahydrocyklo-penta[b]indol-3-ilo)octowego do zastosowania w zaburzeniach związanych z receptorem S1P1 |
| RU2732572C2 (ru) * | 2016-05-31 | 2020-09-21 | Тайхо Фармасьютикал Ко., Лтд. | Сульфонамидное соединение или его соль |
| US10889555B2 (en) | 2016-05-31 | 2021-01-12 | Taiho Pharmaceutical Co., Ltd. | Sulfonamide compound or salt thereof |
| CN106349483A (zh) * | 2016-08-14 | 2017-01-25 | 衡阳师范学院 | 一种含有萘甲羧基与邻菲罗啉的多核钙聚合物及其制备方法与应用 |
| MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
| MX2019009843A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales. |
| MY201832A (en) * | 2017-11-29 | 2024-03-19 | Taiho Pharmaceutical Co Ltd | Sulfonamide compounds and use thereof |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| CN119751336A (zh) | 2018-09-06 | 2025-04-04 | 艾尼纳制药公司 | 可用于治疗自身免疫性病症和炎性病症的化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050107345A1 (en) * | 2002-03-01 | 2005-05-19 | Doherty George A. | Aminoalkylphosphonates and related compounds as edg receptor agonists |
| US7309721B2 (en) * | 2002-03-01 | 2007-12-18 | Merck + Co., Inc. | Aminoalkylphosphonates and related compounds as Edg receptor agonists |
| US8022225B2 (en) * | 2004-08-04 | 2011-09-20 | Taisho Pharmaceutical Co., Ltd | Triazole derivative |
| EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
-
2007
- 2007-01-10 TW TW096100942A patent/TW200736234A/zh unknown
- 2007-01-15 EP EP07700377A patent/EP1979332A1/en not_active Withdrawn
- 2007-01-15 AU AU2007206746A patent/AU2007206746A1/en not_active Abandoned
- 2007-01-15 UY UY30094A patent/UY30094A1/es unknown
- 2007-01-15 US US12/160,979 patent/US20100197749A1/en not_active Abandoned
- 2007-01-15 CA CA002636120A patent/CA2636120A1/en not_active Abandoned
- 2007-01-15 WO PCT/GB2007/000090 patent/WO2007083089A1/en not_active Ceased
- 2007-01-15 BR BRPI0706402-0A patent/BRPI0706402A2/pt not_active Application Discontinuation
- 2007-01-15 JP JP2008550831A patent/JP2009523774A/ja active Pending
- 2007-01-15 CN CNA2007800024150A patent/CN101370794A/zh active Pending
- 2007-01-15 KR KR1020087019942A patent/KR20080094913A/ko not_active Withdrawn
- 2007-01-17 AR ARP070100201A patent/AR059138A1/es not_active Application Discontinuation
-
2008
- 2008-07-02 IL IL192591A patent/IL192591A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2636120A1 (en) | 2007-07-26 |
| CN101370794A (zh) | 2009-02-18 |
| BRPI0706402A2 (pt) | 2011-03-29 |
| JP2009523774A (ja) | 2009-06-25 |
| AR059138A1 (es) | 2008-03-12 |
| KR20080094913A (ko) | 2008-10-27 |
| EP1979332A1 (en) | 2008-10-15 |
| IL192591A0 (en) | 2009-02-11 |
| WO2007083089A1 (en) | 2007-07-26 |
| US20100197749A1 (en) | 2010-08-05 |
| TW200736234A (en) | 2007-10-01 |
| AU2007206746A1 (en) | 2007-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30094A1 (es) | Compuestos químicos | |
| UY30282A1 (es) | Compuestos quimicos | |
| UY29300A1 (es) | Compuestos quimicos | |
| ECSP099322A (es) | Compuestos químicos | |
| UY29093A1 (es) | Derivados de 4-oxo-3. 4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones que los contienen, procesos de preparación y aplicaiones. | |
| UY31281A1 (es) | Aminas, benzamidas y sulfonamidas {[4-(5,6-dimetil-2-piridin-2-il-piridin-3-il) oxipiridin-2-il]amino} sustituidas, sus sales farmacéuticamente aceptables, composiciones contenniéndolas y aplicaciones. | |
| UY30547A1 (es) | Derivados n-sustituidos de la 6-piridin-4-il quinazolin-2-amina, sus estereoisomeros y sales farmacéuticamente aceptables, proceso de preparacion, composiciones y aplicaciones. | |
| UY28990A1 (es) | Nuevos derivados de benceno 1, 3-amino carbonilo como inhibidores de b-raf, composiciones farmacéuticas que los contienen, procesos de preparación y uso. | |
| ECSP099382A (es) | Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i | |
| UY29092A1 (es) | Derivados de 4-oxo-3,4-dihidroquinazolin-6-carboxamida, inhibidores de b-raf, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
| CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
| CO6491058A2 (es) | Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos | |
| ECSP12012065A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos | |
| CR11854A (es) | Compuestos de piridina | |
| NI201500123A (es) | Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico | |
| CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
| PA8622401A1 (es) | Derivados de acido 7-fenilamino-4-quinolona-3-carboxilico,procesos para su preparacion y su uso como medicamentos | |
| ECSP13012967A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| UY28122A1 (es) | Nuevos derivados de fluoroglicósidos heterocíclicos, medicamentos que contienen estos compuestos, y el uso de los mismos. | |
| GT200800187A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| ECSP099722A (es) | Compuestos de pirido [2, 3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cáncer | |
| ECSP099425A (es) | Derivados de amina y su uso en enfermedades mediadas por el adrenorecetor beta 2 | |
| DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
| UY30880A1 (es) | 7-alcoxicinolin-3-carboxamidas sustituidas y sales farmacéuticamente aceptables de las mismas, procedimientos de preparacion y aplicaciones | |
| MX2011013869A (es) | Agentes antihelminticos y su uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DESI | Application deemed to be withdrawn |
Effective date: 20120605 |